DelveInsight’s, “Small Lymphocytic Lymphoma Pipeline Insight, 2025” report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in Small Lymphocytic Lymphoma pipeline landscape.

The FDA granted accelerated approval to pirtobrutinib for the treatment of adults with chronic lymphocytic leukemia or small lymphocytic lymphoma. The indication applies to use of the agent in adults ...

Results from BRUIN CLL-321 show Lilly's pirtobrutinib reduced the risk of disease progression or death by 46% compared to idelalisib plus rituximab or bendamustine plus rituximab Pirtobrutinib ...

Please provide your email address to receive an email when new articles are posted on . Zanubrutinib induced a superior overall response rate compared with ibrutinib among patients with relapsed or ...

As therapy for chronic lymphocytic leukemia (CLL) continues to evolve, 2025 brought research, regulatory news, and expert ...

Venetoclax and ibrutinib are therapeutic agents for CLL. Continued approval required further verification and description of clinical benefit in confirmatory trials. Gilead Sciences has voluntarily ...

Eli Lilly and Co., through its Loxo@Lilly oncology unit, secured its second accelerated approval for non-covalent Bruton’s tyrosine kinase (BTK) inhibitor Jaypirca (pirtobrutinib), this time to treat ...

Characterizing outcomes in severe cytopenias by 3 months in BCMA and CD19 CAR-T cell therapies: A single institution experience. This is an ASCO Meeting Abstract from the 2023 ASCO Annual Meeting I.

In the BRUIN Phase 1/2 trial, adult patients with CLL/SLL who have received at least two lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor, achieved an overall response rate of 72% ...

Prognostic significance of blood counts at time of complete remission in acute myeloid leukemia No significant financial relationships to disclose. This is an ASCO Meeting Abstract from the 2008 ASCO ...

--Eli Lilly and Company today announced that the U.S. Food and Drug Administration approved Jaypirca ® for the treatment of adult patients with chronic lymphocytic leukemia or small lymphocytic ...